IBEX LTD (IBEX)

BMG4690M1010 - Common Stock

15.01  +0.5 (+3.45%)

After market: 15.01 0 (0%)

Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to IBEX. IBEX was compared to 86 industry peers in the IT Services industry. IBEX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IBEX scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, IBEX could be worth investigating further for value investing!.



8

1. Profitability

1.1 Basic Checks

IBEX had positive earnings in the past year.
In the past year IBEX had a positive cash flow from operations.
Each year in the past 5 years IBEX has been profitable.
IBEX had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

IBEX has a Return On Assets of 12.30%. This is amongst the best in the industry. IBEX outperforms 89.29% of its industry peers.
IBEX has a Return On Equity of 23.49%. This is amongst the best in the industry. IBEX outperforms 88.10% of its industry peers.
IBEX has a better Return On Invested Capital (14.44%) than 85.71% of its industry peers.
IBEX had an Average Return On Invested Capital over the past 3 years of 10.19%. This is below the industry average of 13.14%.
The 3 year average ROIC (10.19%) for IBEX is below the current ROIC(14.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.3%
ROE 23.49%
ROIC 14.44%
ROA(3y)7.62%
ROA(5y)6.54%
ROE(3y)18.75%
ROE(5y)46.52%
ROIC(3y)10.19%
ROIC(5y)10.92%

1.3 Margins

Looking at the Profit Margin, with a value of 7.15%, IBEX is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
In the last couple of years the Profit Margin of IBEX has grown nicely.
With a decent Operating Margin value of 8.04%, IBEX is doing good in the industry, outperforming 63.10% of the companies in the same industry.
In the last couple of years the Operating Margin of IBEX has grown nicely.
IBEX has a better Gross Margin (71.23%) than 88.10% of its industry peers.
Industry RankSector Rank
OM 8.04%
PM (TTM) 7.15%
GM 71.23%
OM growth 3Y17.17%
OM growth 5YN/A
PM growth 3Y46.39%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IBEX is creating some value.
IBEX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IBEX has less shares outstanding
The debt/assets ratio for IBEX has been reduced compared to a year ago.

2.2 Solvency

IBEX has an Altman-Z score of 3.53. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.53, IBEX is in the better half of the industry, outperforming 65.48% of the companies in the same industry.
The Debt to FCF ratio of IBEX is 0.05, which is an excellent value as it means it would take IBEX, only 0.05 years of fcf income to pay off all of its debts.
IBEX has a Debt to FCF ratio of 0.05. This is amongst the best in the industry. IBEX outperforms 91.67% of its industry peers.
IBEX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With an excellent Debt to Equity ratio value of 0.00, IBEX belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Altman-Z 3.53
ROIC/WACC1.32
WACC10.94%

2.3 Liquidity

IBEX has a Current Ratio of 2.28. This indicates that IBEX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IBEX (2.28) is better than 72.62% of its industry peers.
A Quick Ratio of 2.28 indicates that IBEX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.28, IBEX is in the better half of the industry, outperforming 72.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.28

4

3. Growth

3.1 Past

The earnings per share for IBEX have decreased strongly by -10.66% in the last year.
IBEX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 58.42% yearly.
Looking at the last year, IBEX shows a decrease in Revenue. The Revenue has decreased by -1.19% in the last year.
Measured over the past years, IBEX shows a quite strong growth in Revenue. The Revenue has been growing by 8.86% on average per year.
EPS 1Y (TTM)-10.66%
EPS 3Y58.42%
EPS 5YN/A
EPS growth Q2Q-29.03%
Revenue 1Y (TTM)-1.19%
Revenue growth 3Y8.89%
Revenue growth 5Y8.86%
Revenue growth Q2Q-4.85%

3.2 Future

The Earnings Per Share is expected to grow by 11.82% on average over the next years. This is quite good.
IBEX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.14% yearly.
EPS Next Y6.72%
EPS Next 2Y9.01%
EPS Next 3Y11.82%
EPS Next 5YN/A
Revenue Next Year-3.31%
Revenue Next 2Y0.84%
Revenue Next 3Y3.14%
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 8.53, which indicates a very decent valuation of IBEX.
IBEX's Price/Earnings ratio is rather cheap when compared to the industry. IBEX is cheaper than 94.05% of the companies in the same industry.
IBEX is valuated cheaply when we compare the Price/Earnings ratio to 26.42, which is the current average of the S&P500 Index.
IBEX is valuated cheaply with a Price/Forward Earnings ratio of 6.72.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 96.43% of the companies listed in the same industry.
IBEX is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 8.53
Fwd PE 6.72

4.2 Price Multiples

IBEX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IBEX is cheaper than 90.48% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IBEX is valued cheaply inside the industry as 84.52% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.56
EV/EBITDA 4.09

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of IBEX may justify a higher PE ratio.
PEG (NY)1.27
PEG (5Y)N/A
EPS Next 2Y9.01%
EPS Next 3Y11.82%

0

5. Dividend

5.1 Amount

No dividends for IBEX!.
Industry RankSector Rank
Dividend Yield N/A

IBEX LTD

NASDAQ:IBEX (3/27/2024, 8:19:58 PM)

After market: 15.01 0 (0%)

15.01

+0.5 (+3.45%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap263.73M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 8.53
Fwd PE 6.72
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.27
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.3%
ROE 23.49%
ROCE
ROIC
ROICexc
ROICexgc
OM 8.04%
PM (TTM) 7.15%
GM 71.23%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.28
Quick Ratio 2.28
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-10.66%
EPS 3Y58.42%
EPS 5Y
EPS growth Q2Q
EPS Next Y6.72%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-1.19%
Revenue growth 3Y8.89%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y